RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

This trial is testing a laboratory test called the RNA Disruption Assay (RDA) that analyzes biopsy samples taken during chemotherapy before breast cancer surgery, to predict how well the cancer is responding to treatment — potentially allowing doctors to personalize therapy earlier. **You may be eligible if...** - You are a woman aged 18 or older - You have been newly diagnosed with early- to mid-stage (Stage I, II, or III) invasive breast cancer - Your tumor is at least 1 cm in size - You are scheduled to receive chemotherapy before surgery (called neoadjuvant chemotherapy) - You are willing to have two small tissue biopsies taken during your chemotherapy course **You may NOT be eligible if...** - You have already had surgery, radiation, or chemotherapy for this breast cancer - Your breast cancer has spread to distant organs (Stage IV) - You have cancer in both breasts or multiple separate tumors - You are currently pregnant or breastfeeding - You have had another cancer in the past (except treated early-stage skin or cervical cancer) Talk to your doctor to see if this trial is right for you.